Who Owns Januvia?
Januvia is owned by Merck & Co., a publicly traded American multinational pharmaceutical company. Januvia is Merck's diabetes treatment. Merck is headquartered in Rahway, New Jersey, USA and trades on NYSE (MRK).
Januvia Timeline
Who Owns Januvia?
- Parent Company: Merck & Co.
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: NYSE: MRK
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Januvia | Merck & Co. | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
Januvia on AmazonHistory of Januvia
- Founded: 2006
- Founders: Merck & Co. (internal development)
Januvia (sitagliptin) was developed by Merck & Co. through research into dipeptidyl peptidase-4 (DPP-4) inhibition for treating type 2 diabetes. The DPP-4 enzyme degrades incretin hormones that stimulate insulin secretion. By inhibiting DPP-4, sitagliptin prolongs the action of these hormones, increasing insulin secretion and reducing blood sugar levels in type 2 diabetes patients.
The FDA approved Januvia in October 2006 as a once-daily oral treatment for type 2 diabetes. It was the first DPP-4 inhibitor to reach the market. Merck subsequently developed a combination product, Janumet (sitagliptin plus metformin), which was approved in 2007. Januvia quickly became one of the most prescribed diabetes medications globally, offering patients a new mechanism of action with a favorable side effect profile compared to older diabetes drugs.
Following its US approval, Januvia received regulatory approval in numerous countries worldwide, including European Union markets (approved by the EMA in 2007), Japan, and many others. The drug became a standard treatment option for type 2 diabetes, particularly for patients who did not achieve adequate blood sugar control with metformin alone.
Januvia's manufacturing process gained recognition for environmental innovation. Merck developed a second-generation synthesis for sitagliptin using a biocatalytic route that won the 2006 Presidential Green Chemistry Challenge Award. This process creates significantly less waste per pound of active ingredient and increases yield by nearly 50 percent compared to the original synthesis.
In recent years, Januvia has faced patent expiration concerns. Key patents for sitagliptin have been subject to litigation, and generic competition was anticipated. In 2025, Merck significantly reduced Januvia's price as part of broader pharmaceutical pricing changes, which affected the drug's revenue trajectory. Merck has focused on new product launches, particularly in oncology and vaccines, to offset potential revenue declines from Januvia and other products facing generic competition.
About Merck & Co.
What does Merck & Co. own?
Merck & Co. owns a portfolio of pharmaceutical products, vaccines, and animal health products. The company's major brands include Keytruda (oncology immunotherapy), Gardasil (HPV vaccine), Winrevair (pulmonary arterial hypertension), Januvia/Janumet (diabetes), Bridion (anesthesia reversal), Ohtuvayre (COPD), and various other prescription medicines. Merck also operates an animal health division under the Merck Animal Health brand, providing veterinary medicines and vaccines.
Is Merck & Co. publicly traded?
Yes. Merck & Co., Inc. trades on the New York Stock Exchange under ticker symbol MRK. The company has no controlling shareholder, with ownership distributed among institutional investors including Vanguard Group, BlackRock, and State Street.
What is Merck's annual revenue?
In FY2024, Merck reported worldwide sales of $64.2 billion, a 7% increase from FY2023. The Pharmaceutical segment generated approximately $57.4 billion and the Animal Health segment approximately $5.8 billion. Keytruda alone accounted for approximately $29.5 billion in FY2024 sales.
Who is Merck's CEO?
Robert M. Davis has served as Chairman and Chief Executive Officer of Merck & Co. since 2021, succeeding Kenneth Frazier. Davis has led the company's strategy of building a post-Keytruda pipeline through acquisitions and internal research investment.
What is Keytruda and why is it important to Merck?
Keytruda (pembrolizumab) is a PD-1 immune checkpoint inhibitor approved for more than 40 cancer indications. It is the world's best-selling prescription medicine, generating approximately $29.5 billion in FY2024 sales, representing roughly 46% of Merck's total revenue. Keytruda's primary U.S. patent expires in 2028, which will allow biosimilar competition and represents the company's most significant strategic challenge.
What is the difference between Merck & Co. and Merck KGaA?
Merck & Co., Inc. (NYSE: MRK) is an American pharmaceutical company headquartered in Rahway, New Jersey, known as MSD outside the United States and Canada. Merck KGaA is a separate German pharmaceutical and chemical company headquartered in Darmstadt, Germany. The two companies have had no ownership relationship since 1917, when the U.S. government seized German-owned assets and the American entity was incorporated as an independent company.
What is Winrevair?
Winrevair (sotatercept) is a treatment for pulmonary arterial hypertension approved by the FDA in March 2024. It was acquired through Merck's $11.5 billion acquisition of Acceleron Pharma in 2021. Winrevair generated $419 million in FY2024 sales and is expected to become a significant revenue contributor as it addresses a rare disease with limited treatment options.
- Founded: 1668
- Headquarters: Rahway, New Jersey, USA
- Company Type: Publicly Traded
- Stock: NYSE: MRK
- Revenue: $64.2B (FY2024)
- Employees: ~72,000
Where Is Januvia Made / Based?
- Headquarters: Rahway, New Jersey, USA
- Manufacturing / Operations: United States, Belgium, Germany, Ireland
Januvia Categories & Tags
Januvia Sustainability & Ethics
Januvia's manufacturing process received the 2006 Presidential Green Chemistry Challenge Award from the US Environmental Protection Agency. Merck developed a second-generation biocatalytic synthesis for sitagliptin that creates approximately 220 pounds less waste per pound of active ingredient and increases yield by nearly 50 percent. The process uses an engineered enzyme catalyst and requires only three steps compared to the original eight-step synthesis.
Merck operates under pharmaceutical industry environmental, health, and safety regulations across all manufacturing facilities. The company publishes annual ESG reports covering environmental performance, access to health, and ethical standards.
Merck offers patient assistance programs through Merck Helps, which provides Januvia at reduced or no cost to eligible patients who cannot afford the medication.
Awards & Recognition
- Presidential Green Chemistry Challenge Award (2006): Merck received this EPA award for the innovative biocatalytic synthesis of sitagliptin (Januvia's active ingredient), which significantly reduces waste and increases manufacturing yield.
- FDA Approval (2006): Januvia was the first DPP-4 inhibitor approved by the FDA for type 2 diabetes treatment.
- Global Regulatory Approvals: Januvia has received regulatory approval in over 80 countries worldwide, including EU (EMA, 2007), Japan, Canada, and Australia.
Januvia Recalls & Controversies
Pancreatic Cancer Litigation: Januvia has faced hundreds of lawsuits alleging links between the medication and pancreatic cancer. Plaintiffs claimed Merck failed to adequately warn about potential risks of incretin mimetic drugs. The scientific evidence regarding a causal relationship between DPP-4 inhibitors and pancreatic cancer remains contested, and the FDA has not concluded that these drugs cause pancreatic cancer.
FDA Safety Investigation (2013): In March 2013, the FDA announced it was investigating potential safety issues regarding incretin mimetic drugs, including DPP-4 inhibitors like Januvia and GLP-1 analogues. The FDA clarified it had not reached conclusions about safety risks but the investigation created uncertainty among patients and healthcare providers.
Price Reduction Controversy (2025): Merck significantly reduced Januvia's price in 2025, which exposed complex relationships between pharmaceutical companies, pharmacy benefit managers (PBMs), and insurance providers. While the price reduction was intended to benefit patients, it raised questions about medication pricing transparency and PBM profit dynamics.
No major product recalls have been associated with Januvia.
Brands Owned by Merck & Co.
Healthcare PharmaceuticalsBridion
Owned by Merck & Co.
Prescription medication for reversing neuromuscular blockade during anesthesia, manufactured and marketed by Merck & Co.
anesthesianeuromuscular-blockadereversal
Healthcare PharmaceuticalsCozaar
Owned by Merck & Co.
Prescription blood pressure medication, the first angiotensin II receptor blocker, approved by the FDA in 1995.
blood-pressurehypertensionarb
Healthcare PharmaceuticalsEmend
Owned by Merck & Co.
Prescription antiemetic medication (aprepitant) for preventing chemotherapy-induced nausea and vomiting, owned by Merck & Co. (NYSE: MRK). FDA approved in 2003. U.S. patent expired in 2019 with generic versions available.
antiemeticnauseavomiting
Healthcare PharmaceuticalsGardasil
Owned by Merck & Co.
Prescription human papillomavirus vaccine for preventing cervical cancer and other HPV-related cancers, manufactured and marketed by Merck & Co.
vaccinehpvcancer-prevention
Healthcare PharmaceuticalsIsentress
Owned by Merck & Co.
Prescription HIV antiretroviral medication (raltegravir) developed by Merck and Co., FDA-approved in 2007 as the first integrase strand transfer inhibitor for HIV-1 treatment.
hivantiretroviralintegrase-inhibitor
Healthcare PharmaceuticalsKeytruda
Owned by Merck & Co.
Prescription PD-1 checkpoint inhibitor immunotherapy for multiple cancers, owned by Merck and Co. (NYSE: MRK).
oncologycancer-treatmentimmunotherapy
Januvia Ownership: Pros & Cons
Advantages
- +Backed by Merck's manufacturing infrastructure, regulatory expertise, and global distribution network
- +Extensive clinical trial data supporting safety and efficacy, with nearly 20 years of post-marketing experience
- +Oral administration (once-daily tablet) is convenient compared to injectable alternatives
- +Favorable side effect profile compared to older diabetes medications
- +Green chemistry manufacturing process reduces environmental impact
Considerations
- -Increasing competition from GLP-1 receptor agonists and SGLT-2 inhibitors that offer additional cardiovascular and renal benefits
- -Patent expiration and anticipated generic competition will reduce revenue
- -Pancreatic cancer litigation and safety concerns have created reputational and legal costs
- -Price reductions in 2025 will affect revenue trajectory
- -DPP-4 inhibitors generally produce smaller blood sugar reductions compared to GLP-1 agonists
Frequently Asked Questions About Januvia
Sources & Further Reading
Competitors to Januvia
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Sanofi | France | 2000 | Premium | Global | All-ages |
Competitive Analysis
Market Positioning: Januvia competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Independent Alternatives to Januvia
Looking for brands with different ownership structures? These similar brands are not owned by Merck & Co., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsPharmacy Direct
Owned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
online-pharmacymail-orderdigital-health
Privately Owned
Pharmacy Direct is privately owned, unlike Januvia which is under a publicly traded parent company.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike Januvia which is under a publicly traded parent company.
Healthcare PharmaceuticalsBausch + Lomb
Owned by Bausch + Lomb Corporation
Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.
contact-lensesvision-carebausch-lomb
Publicly Traded
Bausch + Lomb operates independently without a large parent corporation.
Healthcare PharmaceuticalsGoodRx
Owned by GoodRx Holdings, Inc.
American healthcare technology platform providing prescription drug price comparison, discount coupons, and telehealth services to help consumers find affordable healthcare options.
prescription-savingshealthcare-technologydrug-prices
Publicly Traded
GoodRx operates independently without a large parent corporation.
Healthcare PharmaceuticalsHerbalife
Owned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
nutritiondietary-supplementsweight-management
Publicly Traded
Herbalife operates independently without a large parent corporation.
Healthcare PharmaceuticalsRetavase
Owned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
pharmaceuticalthrombolyticreteplase
Privately Owned
Retavase is privately owned, unlike Januvia which is under a publicly traded parent company.
Merck & Co. Stock Information
Jobs at Merck & Co.
Latest News About Januvia
Related Articles About Januvia
View more articles
Guides
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Who Brands StaffFeb 4, 2026
PharmaceuticalBrand OwnershipHealthcare
Entertainment
Toy Brand Ownership: From LEGO to Hasbro
LEGO is family-owned by the Kirk Kristiansens. Hasbro and Mattel are Wall Street-owned. Bandai Namco owns Tamagotchi. Discover who owns the biggest toy brands and why it matters. Explore our database.
Who Brands StaffSep 4, 2026
ToysLegoHasbro
Pop Culture
Video Game Brands and Their Corporate Parents
EA sold for $55B to Saudi Arabia's PIF, Silver Lake and Kushner's Affinity. Microsoft bought Activision Blizzard for $75.4B. Tencent owns Riot, Supercell, and stakes in Epic. Sony bought Bungie for $3.6B. Discover video game brands and their corporate parents.
Who Brands StaffSep 3, 2026
Video GamesAcquisitionsEa
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription
Brandpharmaceutical
Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.
Brand in Healthcare & Pharmaceuticals
thrombolyticstroke-treatment